Figure 1:

(A) Study rationale for using methylated DNA markers compared to mutation-based biomarker in metastatic colorectal cancer and B) overview of three parallel studies to address primary aims. 1) Primary and Metastatic Tissue MDM Concordance Study to assess concordance of MDMs between primary and metastatic CRC over time; 2) MDM Plasma CRC Early Primary Detection Study to measure sensitivity and specificity of MDMs for early detection of primary CRC; 3) MDM Plasma CRC Surveillance Study to measure sensitivity and specificity of MDMs for detection of recurrent and metastatic CRC. MDM: methylated DNA marker; CRC: colorectal cancer; NED: no radiographic evidence of disease.